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Use of Chromium Picolinate and Biotin in the
Management of Type 2 Diabetes: An Economic Analysis
JOSEPH P. FUHR, Jr., Ph.D.,1,2 HOPE HE, M.A. M.P.A.,2 NEIL GOLDFARB, B.A.,2
and DAVID B. NASH, M.D., M.B.A.2
ABSTRACT
This paper addresses the potential economic benefits of chromium picolinate plus biotin (Di-
achrome®) use in people with Type 2 diabetes (T2DM). The economic model was developed
to estimate the impact on health care systems’ costs by improved HbA1C levels with chromium
picolinate plus biotin (Diachrome). Lifetimes cost savings were estimated by adjusting a
benchmark from the literature, using a price index to adjust for inflation. The cost of diabetes
is highly dependent on the HbA1C level with higher initial levels and higher annual incre-
ments increasing the cost. Improvement in glycemic control has proven to be cost-effective
in delaying the onset and progression of T2DM, reducing the risk for diabetes-associated com-
plications and lowering utilization and cost of care. Chromium picolinate plus biotin (Di-
achrome) showed greater improvement of glycemic control in poorly controlled T2DM pa-
tients (HbA1C 10%) compared to their better controlled counterparts (HbA1C  10%). This
improvement was additive to that achieved by oral hypoglycemic medications and correlates
to calculated levels of cost savings. Average 3-year cost savings for chromium picolinate plus
biotin (Diachrome) use could range from $1,636 for a poorly controlled patient with diabetes
without heart diseases or hypertension, to $5,435 for a poorly controlled patient with diabetes,
heart disease, and hypertension. Average 3-year cost savings was estimated to be between
$3.9 billion and $52.9 billion for the 16.3 million existing patients with diabetes. Chromium
picolinate plus biotin (Diachrome) use among the 1.17 million newly diagnosed patients with
T2DM each year could deliver lifetime cost savings of $42 billion, or $36,000 per T2DM pa-
tient. Affordable, safe, and convenient, chromium picolinate plus biotin (Diachrome) could
prove to be a cost-effective complement to existing pharmacological therapies for controlling
T2DM. (Disease Management 2005;8:265–275)
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INTRODUCTION
DIABETES is a serious, costly metabolism dis-order affecting 6.3% of the US population,
or approximately 18.2 million people.1 Type 2
diabetes (T2DM) accounts for 90%–95% of all di-
abetes and affects more than 16.3 million adult
Americans, incurring substantial economic bur-
den to the individual and the society.2 The risk
and prevalence of T2DM increases steadily with
age, and nearly half of all people with T2DM are
older than 65 years.1,3 By age 60, approximately
1Widener University, Department of Economics, Chester, Pennsylvania.
2Department of Health Policy, Thomas Jefferson University, Philadelphia, Pennsylvania.
10% of the population is estimated to have
T2DM.3 Moreover, approximately 9% of pa-
tients with T2DM develop microvascular dis-
ease, and 20% have a macrovascular complica-
tion within 9 years of diagnosis.4
T2DM is characterized by insulin deficiency,
insulin resistance, and impaired insulin secre-
tion. Insulin resistance and abnormally ele-
vated blood sugar levels are its first signs and
the underlying causes of the diabetes-associ-
ated complications.5,6 The risk of diabetes rises
relative to the degree of insulin resistance.6 As
a result, many T2DM medications such as sul-
fonylureas, non-sulfonylurea secretagogues,
biguanides (eg, metformin), and the carbohy-
drate blockers (acarbose and miglitol) directly
target insulin resistance by increasing insulin
production in the pancreas, or by decreasing
glucose output through the liver, while the in-
sulin-sensitizing tiazolidinediones (TZDs) tar-
get different key organs to decrease insulin re-
sistance and improve blood glucose uptake
into the cells.7,8 Some nonprescription agents
(nutritional supplements), such as the essential
nutrient chromium, improve insulin sensitiv-
ity, while other nutrients, such as biotin, help
to improve liver and pancreatic function.9 The
nutrient combination of chromium picolinate
plus biotin (as Diachrome) affects both glucose
and lipid pathways and has shown benefits
such as improving insulin sensitivity by in-
creasing the number of cellular insulin recep-
tors and activating these receptors, improving
glucokinase activity in the liver, and improv-
ing pancreatic -islet cell function.10
The treatment goal for T2DM essentially is
to improve glycemic control and to adapt to
medical regimens and lifestyle changes, which
has proved cost-effective.11–13 Good glycemic
control has proved to be cost-effective in de-
laying the onset and progression of the disease,
reducing the risk for complications, and thus
lowering medical utilization and costs of
care.14–16 Glycosylated hemoglobin (HbA1C) is
the accepted standard measure of glycemic
control, while fasting plasma glucose (FPG) in-
dicates immediate diagnosis of diabetes. Indi-
viduals with T2DM are more prone to cardio-
vascular disease (CVD) risk; hence, they also
must closely monitor cardiovascular risk fac-
tors. The high incidence of CVD among people
with T2DM further increases medical utiliza-
tion and costs of care for these individu-
als.4,17,19,72
The UKPDS (United Kingdom Prospective
Diabetes Study) study17 results indicated “that
for every percentage point decrease in HbA1C
(eg, from 9% to 8%), there was a 25% reduction
in diabetes-related deaths, a 7% reduction in
all-cause mortality, and an 18% reduction in
combined fatal and nonfatal myocardial in-
farction.”18 However, the cost of improving
glycemic control can be substantial. For exam-
ple, in the 1997 UKPDS study,19 the costs of in-
tensive and control therapy were $8,020 and
$6,740, respectively. The annual cost in the 1993
Diabetes Control and Complications Trial
(DCCT) study19 was $4,000 for Multiple Daily
Injections (MDI), $5,800 for Continuous Sub-
cutaneous Insulin Injections (CSII), and $1,700
for conventional therapy.
Pharmacological therapy has been effective
in glucose control and usually is initiated when
other methods, such as diet and exercise, fail to
manage blood glucose levels within target
ranges. The UKPDS study showed that the rig-
orous treatment of diabetes using blood glu-
cose-lowering agents can decrease the morbid-
ity and mortality of T2DM. Patients who use
blood glucose-lowering agents have shown
fewer physical symptoms and enhanced well
being,12 and have had a significantly reduced
risk of cardiovascular and microvascular com-
plications.17,20 Available oral hypoglycemic
agents such as sulphonylureas, non-sulfony-
lurea secretagogues, metformin, thiazolidine-
diones, and acarbose have glucose-lowering ef-
ficacy21 but enhance adverse side effects and
other complications related to CVD. These
agents have been clinically shown to reduce
HbA1C levels an average of 0.5%–2.0%. Some
of the adverse side effects are gastrointestinal 
distress, edema, weight gain, hypoglycemic
episodes, hepatoxicity, and congestive heart
failure (Table 1). These adverse effects can lead
to patient intolerance and cessation of therapy,
resulting in poor glycemic control and sub-
stantial costs.8,21,19 As a result, pharmacologi-
cal treatments are not considered the most cost-
effective and safe measures for managing
T2DM, and helping prevent those at high risk
for developing T2DM.2,10
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As the disease progresses, to maintain the
optimum HbA1C levels, it is often necessary
and cost-effective to treat the patient not only
with more than one pharmacological agent (in-
cluding using insulin), but also to complement
the pharmacological treatments with other ad-
junctive therapies such as nutritional mea-
sures.22 Chromium picolinate, when adminis-
tered in combination with biotin (Diachrome),
has shown to be a cost-effective, safe adjunc-
tive treatment.23 Like other nutritional thera-
pies for patients with T2DM, chromium picol-
inate plus biotin (Diachrome) is aimed at
helping patients achieve glycemic control, im-
prove serum lipids, and ultimately reduce risk
of associated complications.24
Economic and health impact of glycemic control
The economic burden of diabetes alone has
grown to $132 billion in 2002, including direct
medical expenditures and the costs of foregone
productivity.1,25 From 1997 to 2002, the per
capita costs of diabetes rose 30%.1,25 The ma-
jority of these costs can be attributed to various
diabetes-associated complications, such as
CVD, which accounts for 52% of costs.26–31 One
study showed patients with diabetes cost an ex-
cess of $3,494 per person, which was 2.4 times
more for diabetic members than for matched
control subjects. In addition, 37.6% of total di-
rect excess costs per patient per year were at-
tributable to long-term complications, and an
additional 4% were due to short-term compli-
cations.26 Moreover, the average direct cost of
managing complications over 30 years was
shown to be $47,240 per patient for those who
had been treated for 5 years and with a mean
HbA1C of 8.4, assuming HbA1C would increase
by 0.15 percentage points annually, other
things being equal.32
Furthermore, the economic burden from im-
pending diabetes is apparent at least 8 years
before diagnosis, with the average diabetes-as-
sociated incremental direct cost of $1,205 per
type 2 diabetic patient per year during the first
8 prediagnostic years.31 A related study found
that the average incremental cost of diabetes
was $2,257 per year during the first 8 postdi-
agnostic years.30 In addition, the cost of dia-
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TABLE 1. ORAL ANTIDIABETES THERAPIES: AVERAGE HBA1C REDUCTION AND SIDE EFFECTS
Average
HbA1c
Class Oral agent reduction Common side effects
Sulfonylureas Glipizide (Glucotrol, Metaglip), 0.8%–2.0%0 Weight gain,
glipizide extended release hypoglycemia
(Glucotrol XL), glyburide
(Diabeta), micronized glyburide
(Glucovance), glimepiride
(Amaryl), chlorpropamide
(Diabinese), tolbutamide,
tolazamide
Non-sulfonylurea Meglitinides—repaglinide 0.5%–2.0%0 Weight gain,
secretagogues (Prandin); nateglinide (Starlix) hypoglycemia
-Glucosidase Acarbose (Precose), miglitol 0.7%–1.0%0 Flatulence, abdominal
inhibitors (Glyset) pain, diarrhea
Biguanides Metformin (Avandamet, Fortamet, 1.5%–2.0%0 Diarrhea, flatulence,
Glucophage), metformin extended nausea and vomiting,
release (Glucophage XR) abdominal pain, lactic
acidosis, vitamin B12
malabsorption
Thiazolidinediones Rosiglitazone (Avandia), 0.5%–1.5%0 Congestive heart
(TZDs) pioglitazone (Actos) failure, hepatoxicity,
peripheral edema,
anemia, weight gain
Nutritional Chromium picolinate and biotin 0.5%–1.94% None
supplement (Diachrome)
betes is highly dependent on the level of
HbA1C. Higher initial levels will increase the
cost as will higher increments per year.32 Im-
provement in glycemic control has proven to
be cost-effective in delaying the onset and pro-
gression of T2DM, reducing the risk for com-
plications associated with diabetes, and lower-
ing utilization and cost of care.17,19,24,29,34,41 A
decrease of HbA1C levels of 1.0 percentage
point could decrease significantly the cost of
healthcare.36
Economic analysis
In a study by Gilmer et al,35 medical care
charges increase for every one percentage point
increase in HbA1C above 7%. So, for an indi-
vidual with an HbA1C value of 6%, successive
increases of one percentage point in HbA1C will
result in cumulative increases in charges of ap-
proximately 4%, 10%, 20%, and 30%, respec-
tively. In another study, using general linear 
regression, Gilmer et al37 estimated the re-
lationship between 3-year health care costs and
baseline HbA1C levels as well as other inde-
pendent variables. The results demonstrated
that a decrease in HbA1C from 10% to 9% could
result in a direct cost savings of $805 over a 3-
year period for patients with diabetes without
heart diseases or hypertension, $1,130 for pa-
tients with diabetes and hypertension, $2,078
for patients with diabetes and heart disease,
and $2675 for patients with diabetes, heart dis-
ease, and hypertension.
Ginsberg et al38 examines the effect of a dis-
ease state management system that emphasizes
a care system for diabetics, primary care pro-
viders, and a team approach. No control group
is involved, and the approach is one of treat-
ment goals and time lines being set for success
with individual therapies. The study estimated
that a reduction in HbA1C from 9.2% to 7.4%
would result in a net direct lifetime cost sav-
ings of $27,000 after payment for the disease
management program. The cost of the diabetes
management program was approximately $800
annually.
In a retrospective study using regression
analysis, Menzin et al39 examined the potential
short-term economic benefits of improved gly-
cemic control on selected short-term complica-
tions of diabetes. Patients improving from fair
(8% to 10%) to good control (less than 8%) had
a reduction in healthcare charges of $410, poor
(greater than 10%) to fair had a $1,660 reduc-
tion, and poor to good had a $2,070 reduction
in health care charges over the same 3-year pe-
riod. The adjusted admissions per 100 were 30,
38, and 74, and the mean adjusted charges were
$2,610, $3,810, and $8,320 over the 3-year pe-
riod.
In comparing patients with different levels
of HbA1C, Wagner40 has shown that “a sus-
tained reduction in HbA1C level among dia-
betic patients is associated with a significant
cost savings within 1–2 years of improvement.”
Wagner used multiple linear regression analy-
sis to estimate the relationship between glyce-
mic control and cost of patients. In his study,
he compared the health utilization and costs
between one group of diabetic patients with a
one percentage point lowering of HbA1C and
another group with no HbA1C improvement.
The total cost in the first year was lower but
not significantly lower. In years 2–4, the cost
savings for the improved cohort were signifi-
cantly lower, and during the last 3 years of the
study the average cost savings ranged between
$685 and $950 per patient per year.
Another paper analyzes the cost savings
from a medical perspective. Testa and Simon-
son41 examined the gains from a societal per-
spective. Patients were randomized and given
either a placebo or glipizide GITS. Both groups
also were put on diet management. The study
was for 12 weeks with the cohort receiving the
treatment experiencing less absenteeism for a
gain of $91 per month, fewer days confined to
bed for a gain of $304 per 1000 person-days,
and fewer restricted-activity days with a gain
of $2,615 per 1000 person-days. There was no
mention of the cost of the program.
Diachrome and its effects on glycemic control
Chromium III, the most stable and nutritional
form of chromium, is a safe trace element essen-
tial for normal carbohydrate and lipid metabo-
lism and potentiates insulin.42–44 Chromium III
has long been shown to improve insulin sensi-
tivity, enhance glucokinase activity, and lower
blood glucose levels in people with insulin re-
sistance and T2DM in both randomized48–57 and
open-label studies.44,45 Chromium picolinate is
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absorbable, safe, and the most widely tested
form of Chromium III.42–68 Biotin is a water-sol-
uble B vitamin known to play a role in glucose
metabolism by helping to break down glucose
as well as enhance insulin sensitivity. Biotin stim-
ulates the activity of glucokinase in the liver and
improves pancreatic -islet cell function.69 Di-
achrome is the formulation of 600 mcg of
chromium (as chromium picolinate) plus 2 mg
of biotin. The supplementation effects of the
combination of chromium picolinate plus biotin
were first proposed in the mid-1990s by re-
searchers at Nutrition 21, Inc.10 Cell culture stud-
ies confirmed a synergistic effect of the combi-
nation on glucose uptake and glycogen synthesis
in skeletal muscle cell cultures.67 Animal models
confirmed these results and further identified an
improvement on lipid profiles, particularly re-
ductions in total cholesterol and increases in
HDL-cholesterol in obese, hyperinsulinemic
rats.70 Clinical research, including both open-la-
bel72 and randomized, double-blind, placebo-
controlled, multicenter trials,71 verified the sig-
nificant effect of chromium picolinate plus biotin
(Diachrome) on both glycemic control and lipid
profiles in patients with T2DM when used as ad-
junctive nutrition therapy to prescription oral an-
tidiabetic agents. This combination appears to
combat insulin resistance, to improve beta cell
function, to enhance postprandial glucose up-
take, and to inhibit excessive hepatic glucose pro-
duction through increasing glycogen syntheses
levels in human skeletal muscle culture.73–77 As
a result, chromium picolinate plus biotin (Di-
achrome), when used with standard treatments,
can significantly improve blood sugar control for
people with and at high risk for T2DM.45,78 In
addition, in a 12-week randomized, double-
blind, placebo-controlled, multicenter study of
453 patients with T2DM,79 chromium picolinate
plus biotin (Diachrome) decreased the mean
HbA1C level by 0.51 (from 8.71 to 8.20) percent-
age points for patients with T2DM who had been
taking oral antihyperglycemic drugs for at least
the past 6 months. The more poorly controlled
patients (based on baseline HbA1C levels)
achieved the greatest improvements in their gly-
cemic control by the end of the study. For pa-
tients who had baseline HbA1C levels of at least
10%, the mean HbA1C levels decreased by 1.78
(from 11.07 to 9.29) percentage points, whereas
for those who had baseline levels of at least 11%,
the mean HbA1C levels decreased by 1.96 (from
11.86 to 9.90) percentage points (Fig. 1).
The only difference pre- and post-study was
the use of chromium picolinate plus biotin (Di-
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FIG. 1. Diachrome study results. Effect on HbA1c levels. All, data from all subjects with baseline and final visits;
n% , data from subjects with baseline HbA1c levels  n%; *, sig. diff. (p  0.01) using ANCOVA (treatment * base-
line HbA1c); **, sig. diff. (p  0.02) compared to placebo.
achrome).80 Two randomized, double-blind,
placebo-controlled multicenter prospective
studies further confirm the findings of im-
proved glycemic control and lipid profiles in
T2DM from this large prospective trial.79,81,82
Chromium picolinate plus biotin (Diachrome)
was studied as adjunctive nutritional therapy
in patients with T2DM. The resulting im-
provement in glycemic control observed in
each of these clinical trials was beyond that al-
ready achieved by use of the oral hypoglycemic
medications. The purpose of this study is to es-
timate the potential cost savings that result
from the decrease in HbA1C through the use of
Diachrome. This paper addresses the potential
economic benefits of chromium picolinate plus
biotin (Diachrome®) use in people with T2DM.
METHODS AND RESULTS
A 12-week clinical study showed that the use
of Diachrome significantly decreased the aver-
age HbA1C at all levels of initial HbA1C (p 
0.05). For example, for all patients in this study
receiving Diachrome the mean HbA1C de-
creased by 0.51 from 8.71 to 8.20, and the 95%
confidence interval for the group after the
study was 8.20  0.16 (Fig. 1).
At all baseline levels Diachrome outper-
formed the placebo. However, only at levels of
baseline HbA1C of at least 10% was the differ-
ence statistically significant (p  0.02). In pa-
tients with baseline levels of at least 10%
HbA1C, the average HbA1C level decreased by
1.78 percentage points with Diachrome com-
pared to 0.78 percentage points with the
placebo (Fig. 1). The baseline average HbA1C in
the Diachrome group was 11.07% whereas af-
ter the study the average HbA1C was 9.29 with
a 95% confidence interval of 9.29  0.53.
Chromium picolinate plus biotin (Diachrome)
is a relatively low-cost adjunct method of con-
trolling HbA1C for T2DM. The introductory cost
of the recommended tablet per day is $19.95 per
60-count bottle, and the annual cost would be
less than $120, which is considerably less than
the cost of intensive and control therapies that
have been examined in other studies. The po-
tential clinical and economic benefits, therefore,
could be considerable. Based on the literature re-
view and research findings, we constructed var-
ious estimates of the potential benefits of the use
of chromium picolinate plus biotin (Diachrome)
in T2DM.
The economic model employed to estimate
the potential economic benefit from the use of
chromium picolinate plus biotin (Diachrome)
began with the establishment of a benchmark
value for the direct cost savings reported in the
literature for decreases in the level of HbA1C.
The benchmark was then adjusted for inflation
using the Medical Care Service Inflation Index
which is a component of the Consumer Price
Index. In some cases extrapolation was utilized
so that the data found in the literature would
conform to the study results. Statistical analy-
sis was used to estimate a range of potential 3-
year cost savings. Lifetime cost savings were
estimated by adjusting a benchmark from the
literature, and using the same price index to ad-
just for inflation.
Wagner et al14 estimated an average annual
cost savings per patient of $685–$950. These
prices were adjusted to 2004 levels by using the
January value of each year’s Medical Care Ser-
vices Inflation Index, a component of the Con-
sumer Price Index. The result was an average
annual cost savings of $978–$1,300.
The Gilmer37 data was extrapolated to reflect
the changes in average HbA1C from 10.62% to
9.18%. Using the data in Gilmer’s study and ad-
justing the Medical Care Service Index to 2004
with 2002 as the base year, the average 3-year
cost savings range from $1,636 for patients with
diabetes only, to $5,435 for a patient with dia-
betes, heart disease, and hypertension (Table 2).
In addition, the retrospective study of Men-
zin et al39 showed that depending on the
change in health category (poor, fair, good), the
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TABLE 2. CHANGES IN HBA1C LEVELS: 
THREE-YEAR COST SAVINGS
Patient classification 11.07%–9.29%
Diabetes with heart disease/ $5,435
hypertension
Diabetes with heart disease $4,221
Diabetes with hypertension $2,296
Diabetes without heart diseases $1,636
or hypertension
Overall $2,791
reduction in health care cost would range from
$410 to $2,070 over a 3-year period. Adjusting
for inflation to 2004 dollars the respective
health care cost reduction over 3 years would
be $562–$2,836.
Existing T2DM patient savings estimate
The medical cost savings from decreasing
HbA1C levels varies among different studies
depending on the assumptions made, such as
severity of illness and initial level of HbA1C. As
a result, the average medical cost savings per
diabetic are difficult to ascertain. However, un-
der all scenarios the annual medical cost sav-
ings is greater than the $120 annual cost of
chromium picolinate plus biotin (Diachrome).
The Menzin study showed the average annual
cost savings to be between $978 and $1300 for
those whose HbA1C decreased by more than
one percentage point. Using sensitivity analy-
sis, three different estimates of annual medical
cost savings of $200, $500, and $1,000 are as-
sumed. The annual potential cost savings of us-
ing chromium picolinate plus biotin (Di-
achrome) are $80 ($200  $120), $380, and $880,
respectively. If the approximately 16.3 million
type 2 diabetics (18.1M  0.9) used chromium
picolinate plus biotin (Diachrome), the esti-
mated 3-year cost savings would be $3.9 bil-
lion, $18.6 billion, or $52.9 billion, respectively
(Table 3). Adding the pain and suffering asso-
ciated with the additional medical complica-
tions, the time cost, and lost productivity, the
savings from the use of chromium picolinate
plus biotin (Diachrome) could be substantial.
Newly diagnosed T2DM patient savings estimate
About 1.3 million people are diagnosed each
year with diabetes, approximately 90% of
whom have T2DM. Using Ginsberg’s estimated
lifetime cost savings of $27,000 ($36,000 in 2004
dollars) per patient with good diabetes control,
just for the newly diagnosed population with
T2DM in 2004, the health care system could
achieve lifetime cost savings of approximately
$42 billion. Adding chromium picolinate plus
biotin (Diachrome) to this regimen appears to
be economically judicious for both newly di-
agnosed patients as well as existing patients
with T2DM, based upon the significant poten-
tial annual and lifetime cost savings.
DISCUSSION
Controlling diabetes in its early stages is nec-
essary, and the progression of the disease is
very expensive. A low-cost intervention could
be beneficial to patients, third party payers, and
society as a whole. Nutrition research is eluci-
dating the important role that certain safe, in-
expensive, essential nutrients may play in dis-
ease prevention and progression by reducing
major risk factors in T2DM. Chromium and bi-
otin are two such affordable essential nutrients
that each have been clinically shown to be safe
and effective in improving glycemic control in
T2DM by enhancing insulin sensitivity and im-
proving glucose metabolism. Research con-
ducted at the United States Department of
Agriculture (USDA) reported an improvement
in glycemic control in T2DM subjects taking
chromium picolinate as adjunct nutrition ther-
apy to oral hypoglycemic medications.60 Rav-
ina et al45 reported on the improvement in gly-
cemic control in subjects with steroid-induced
diabetes who took chromium picolinate. In an-
other study, Ravina et al86 reported on im-
proved glycemic control in patients with type
1 diabetes who added chromium picolinate to
their treatment regimen and reduced their in-
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TABLE 3. TYPE 2 DIABETES POPULATION-WIDE THREE-YEAR COST SAVINGS
Annual cost Annual cost Net benefit of Annual benefit Three-year
Number of savings per of diachrome use of diachrome of diachrome benefit of
Type 2 diabetes patient per patient per patient use diachrome use
16.3M $200 $120 $80 $1.3B $3.9B
16.3M $500 $120 $380 $6.2B $18.6B
16.3M $1000 $120 $880 $14.3B $52.9B
sulin dosage by 50%. Researchers at Harvard
School of Public Health reported an inverse re-
lationship between tissue chromium status and
the incidence of diabetes and cardiovascular
disease.83 Chromium’s effect on glycemic con-
trol has been noted in research literature since
the early 1950s.84,85 Similarly, biotin has an im-
pact on glucose metabolism and insulin sensi-
tivity.87–89 Diachrome, a new, low-cost nutri-
tional therapy for T2DM, is a patented for-
mulation of chromium picolinate and biotin.
Recent clinical trials suggest this composi-
tion improves insulin sensitivity and has a pos-
itive dual effect on both glycemic control and
lipid profiles in T2DM. Furthermore, it is well
tolerated with no significant adverse effects. A
recent controlled study in T2DM demonstrated
a significant decrease in average HbA1C levels
of 1.78 percentage points in patients with ini-
tial levels of at least 9.5%, and 1.96 percentage
points in patients with initial levels of at least
11% over a 12-week course of therapy, with an
increased effect seen in subjects with higher
baseline levels. At the final visit, FPG levels
were lower in the active than in the placebo
group (159 vs. 171 mg/dL). Furthermore, in
subjects with baseline cholesterol 200 mg/dL,
total cholesterol (19.11 vs. 5.87 mg/dL) and
LDL-cholesterol (21.7 vs. 8.2 mg/dL) were
significantly improved in actives compared to
the placebo group.
The significant clinical impact of this non-
prescription nutritional product on both glyce-
mic control and lipid profiles, coupled with the
absence of any product-related adverse events
and its low cost, raise the question of the po-
tential pharmacoeconomic value that this prod-
uct could offer in the management of T2DM.
Based on the clinical results, cost savings cal-
culations indicate that its use could yield a
$36,000 inflation-adjusted lifetime health care
cost savings per patient. An average 3-year cost
savings was estimated to be between $3.9 bil-
lion and $52.9 billion for the 16.3 million exist-
ing patients with diabetes. Diachrome use
among the 1.2 million newly diagnosed pa-
tients with T2DM each year could deliver life-
time cost savings of $42 billion. Affordable,
safe, and convenient, chromium picolinate plus
biotin (Diachrome) could prove to be a cost-ef-
fective complement to existing pharmacologi-
cal therapies for controlling T2DM.
This economic analysis is based on the re-
duction in HbA1C in the clinical trial and the
data used for estimating cost savings are from
the existing literature. Chromium picolinate
plus biotin (Diachrome) also has shown signif-
icant positive clinical effect on lipid profiles.
Additional cost savings can be expected based
on this clinical improvement32 and it is recom-
mended that economic analyses be conducted
to quantify these additional potential cost sav-
ings.
CONCLUSION
Given the chronic nature of the disease and
the devastating potential to develop costly
complications, it is important to use the most
cost-effective measure to help improve glyce-
mic control in people afflicted with and at
higher risk for T2DM. Medical nutrition ther-
apy is one option.
Affordable, safe, convenient, and nutritional,
chromium picolinate plus biotin (Diachrome) is
considered by some “a definitive therapy” for
people with T2DM.73 It is being advocated as
an effective complement to existing therapies
for preventing and treating T2DM, with the po-
tential of reducing the cost of care while main-
taining quality of care and improving the qual-
ity of life for patients with T2DM. Chromium
picolinate plus biotin’s (Diachrome’s) dual ef-
fect on both glycemic control and lipid profiles
is unique among antidiabetes medications. It
has few, if any, negative side effects compared
to other therapies. Our study has shown that
chromium picolinate plus biotin (Diachrome) is
a cost-effective adjunctive therapy in the man-
agement of patients with T2DM and can sub-
stantially decrease the health care costs related
to T2DM.
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